European ISSX
June 29-July 2, 2026 | Basel, Switzerland | Booth 14
The 16th European ISSX European Meeting 2026, held in Basel, Switzerland (June 29–July 2, 2026), will highlight the theme "From Benchside Research to Bedside Reality: DMPK's Next Chapter." This meeting offers a unique platform to connect with leading experts, share cutting-edge research, and gain new perspectives on advancing DMPK from discovery to clinical application.
Breakfast Symposium
Symposium Title: Optimizing PK Strategies for Brain-Targeting Drugs Using Humanized Animal Models
Date: Tuesday, June 30
Time: 7:30am – 8:15am
Location: Sydney Room
Presenter:
Furong Jiao
Abstract: This presentation aims to share key considerations for DMPK strategies during the preclinical development of brain-targeted therapeutics. Key takeaways will include:
1. Complexity and challenges in exposure assessment of brain-targeted drugs
2. Leveraging the advantages of humanized animal models to optimize PK strategies for brain-targeted drugs
3. Preclinical DMPK approaches to support the development of novel drug delivery technologies for brain-targeted therapeutics
Thought Leader Partner Presentation
Title: Mastering siRNA Plasma Protein Binding: Overcoming Artifacts in Ultrafiltration and EMSA for Robust ADME
Date: Wednesday, July 1
Time: 9:40am – 9:55am
Location: Sydney Room
Presenter:
Jie Wang
Abstract: Accurate in vitro plasma protein binding (PPB) assessment is crucial for predicting the distribution, safety, and efficacy of oligonucleotide therapeutics. However, the literature reveals striking discrepancies in siRNA PPB data, largely driven by the choice of assay methodology. This presentation explores the fundamental differences and methodological artifacts between the two predominantly used formats: Ultrafiltration (UF) and Electrophoretic Mobility Shift Assay (EMSA). We will delve into strategies to overcome severe non-specific binding (NSB) in UF and expose the dynamic, condition-dependent artifacts inherent in EMSA. By systematically unraveling these discrepancies, we provide a robust, optimized methodological framework for reliable, regulatory-compliant PPB evaluations, ultimately guiding more accurate ADME profiling in oligonucleotide drug development.
Posters
| Title | Poster # | Presenting author | Presenting time |
|---|---|---|---|
| A Sensitive and Simple LC-MS/MS Method for Simultaneous Determination of GABA and GHB in Plasma | P29 | Lili Xing | Wednesday, July 1 12:00 - 13:30 |
| The Impact of Probe Substrate Selection on Reducing Off-Target Effects in Enzyme Phenotyping of Slow-metabolizing Drugs | P45 | Huan Liu | Wednesday, July 1 12:00 - 13:30 |
| Evaluation of Rat Liver Tritosomes as an In Vitro Lysosomal Model for the Catabolism and Payload Release of an Anti-TfR1 Antibody-siRNA Conjugate | P93 | Hong Zhang | Wednesday, July 1 12:00 - 13:30 |
| Optimizing Preclinical Pharmacokinetic Studies: A High Throughput Approach for Assessing Brain Drug Exposure | P111 | Furong Jiao | Thursday, July 2 12:00 - 12:45 |
| Rapid Determination of Plasma Protein Binding and Dissociation Kinetics Using Dextran-Coated Charcoal Method Assessment and Optimization for Unstable and Highly Bound Compounds | P190 | Jie Wang | Thursday, July 2 12:00 - 12:45 |